PAR3 (1-6) amide (human) (trifluoroacetate salt)
(Synonyms: Proteinase-Activated Receptor 3, TFRGAP-NH2) 目录号 : GC45541
A peptide agonist of PAR1 and PAR2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
PAR3 (1-6) amide is a synthetic peptide agonist of proteinase-activated receptor 1 (PAR1) and PAR2 that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR3 and residues 39-44 of the full-length human sequence. PAR3 (1-6) amide activates PAR1 and PAR2 in Jurkat and HEK cells, inducing calcium accumulation in Jurkat cells, which is reduced following desensitization with the PAR1- and PAR2-selective peptide agonist SFLLR-NH2.1 It decreases the expression of CDC42 in wild-type, but not PAR3 knockdown, PANC-1 cells and reduces invasion of PANC-1 cells.2
References
1. Hansen, K.K., Saifeddine, M., and Hollenberg, M.D. Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells. Immunology 112(2), 183-190 (2004).
2. Segal, L., Katz, L.S., Lupu-Meiri, M., et al. Proteinase-activated receptors differentially modulate in vitro invasion of human pancreatic adenocarcinoma PANC-1 cells in correlation with changes in the expression of CDC42 protein. Pancreas 43(1), 103-108 (2014).
| Cas No. | SDF | ||
| 别名 | Proteinase-Activated Receptor 3, TFRGAP-NH2 | ||
| Canonical SMILES | O=C(O)C(F)(F)F.NC([C@@H]1CCCN1C([C@@H](NC(CNC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@@]([C@@H](C)O)([H])N[H])=O)CC2=CC=CC=C2)=O)=O)=O)C)=O)=O | ||
| 分子式 | C29H46N10O7.XCF3COOH | 分子量 | 646.7 |
| 溶解度 | Water: 1 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5463 mL | 7.7316 mL | 15.4631 mL |
| 5 mM | 0.3093 mL | 1.5463 mL | 3.0926 mL |
| 10 mM | 0.1546 mL | 0.7732 mL | 1.5463 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。